Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16125671 | 0.83 | ALDH1A1 (0.47) | ALDH1A1LMNAHSD17B10NPSR1GLO1 | |
| SCHEMBL20691515 | 0.82 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10NPSR1GLO1 | |
| SCHEMBL10448690 | 0.80 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10NPSR1GLO1 | |
| SCHEMBL2133814 | 0.80 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10NPSR1GLO1 | |
| SCHEMBL20691539 | 0.80 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10NPSR1GLO1 | |
| SCHEMBL9852685 | 0.79 | PRKCA (0.38) | — | |
| SCHEMBL28438273 | 0.78 | CYP4F2 (0.41) | ALDH1A1LMNAHSD17B10NPSR1GLO1 | |
| SCHEMBL11768714 | 0.78 | CYP4F2 (0.41) | ALDH1A1LMNAHSD17B10NPSR1GLO1 | |
| SCHEMBL11201754 | 0.77 | ALDH1A1 (0.45) | ALDH1A1LMNAHSD17B10NPSR1GLO1 | |
| SCHEMBL27486109 | 0.77 | CYP4F2 (0.44) | ALDH1A1LMNAHSD17B10NPSR1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105517574-B | The combination product of hepatitis C virus inhibitors | 百时美施贵宝公司 | 2019-01-18 | — | — | CN | disclosed |
| CN-105517574-A | Combinations of hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2016-04-20 | — | — | CN | disclosed |
| EP-2889289-A1 | Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors | GlaxoSmithKline LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| CN-104302290-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-01-21 | — | — | CN | disclosed |
| US-RE44613-E1 | N-substituted glycine derivatives: hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| CN-101626685-B | N-substituted glycine derivatives: hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2013-03-13 | — | — | CN | disclosed |
| CN-101626685-A | The glycine derivative that N-replaces: hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2010-01-13 | — | — | CN | disclosed |
| EP-2124565-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7608621-B2 | Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production | SMITHKLINE BEECHAM, CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2009032179-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-7109004-B2 | Process for reducing an alpha-keto ester | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040101937-A1 | Process for reducing an alpha-keto ester | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| US-20040087569-A1 | N-heterocyclic bicyclic lactone compounds | NELSON TODD D (US) | 2004-05-06 | — | — | US | disclosed |
| US-6348617-B1 | REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-19 | — | — | US | disclosed |
| US-6348620-B1 | FORMING DESIRED HYDROGENATED DERIVATIVES WITH GOOD TO VERY GOOD YIELDS AND EXCESSES OF ENANTIOMERS | DEGUSSA-HULS AG (DE) | 2002-02-19 | — | — | US | disclosed |
| EP-0937703-A1 | METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |
| US-5710322-A | Optically active iminocarboxylic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0097000-A2 | Amine derivatives | Beecham Wuelfing GmbH & Co KG (DE) | 1983-12-28 | — | — | EP | disclosed |
| US-4411912-A | Insecticidal isovaleric acid esters | ZOECON CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
| US-4243819-A | Substituted amino acids | ZOECON CORPORATION (US) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087569-A1 | N-heterocyclic bicyclic lactone compounds | VIP, NGLY1, NPPA | ALDH1A1 2305/4885LMNA 988/4885HSD17B10 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.